Clinical-stage life science company Eleusis and Silver Spike Acquisition II this afternoon announced that they have mutually agreed to terminate their plan of merger, effective immediately. The decision was based on current unfavorable market conditions, the comapnies said in a press release.
Silver Spike II said intends to continue efforts to identify a prospective target business.
The Eleusis deal had been expected to generate gross proceeds of up to $288 million with an implied combined enterprise value of $446 million. Read more.
